Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto’s Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis
Authors Wu Y, Han J, Vladimirovna KE, Zhang S, Lv W, Zhang Y, Jamaspishvili E, Sun J, Fang Q, Meng J, Qiao H
Received 8 August 2019
Accepted for publication 20 September 2019
Published 14 October 2019 Volume 2019:12 Pages 8479—8489
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Cho
Yanmeizhi Wu,1 Jun Han,1 Kazakova Elena Vladimirovna,1 Shumei Zhang,2 Wenhua Lv,2 Yan Zhang,3 Esma Jamaspishvili,1 Jingxue Sun,1 Qingxiao Fang,1 Jingjing Meng,1 Hong Qiao1
1Department of Endocrinology, No.2 Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People’s Republic of China; 2Department of Epigenetics, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang Province, People’s Republic of China; 3Department of Bioinformatics and Computational Epigenetics, College of Life and Science and Technology, Harbin Institute of Technology, Harbin, Heilongjiang Province, People’s Republic of China
Correspondence: Hong Qiao
Department of Endocrinology, No.2 Affiliated Hospital of Harbin Medical University, No. 148 Baojian Road, Nangang District, Harbin, Heilongjiang Province, People’s Republic of China
Tel +86 13945677355
Introduction: PTC is not generally considered a lethal disease, but prone to recurrence as the prognosis. Hashimoto’s thyroiditis (HT) is an important factor that affects the prognosis of papillary thyroid carcinoma (PTC). It is crucial to find biomarkers to identify the combination of HT with PTC and to predict the prognosis.
Methods: RNASeq data from the Cancer Genome Atlas (TCGA) database was used to screen differentially expressed genes (DEGs) of PTC with HT via the edgeR package of R software version 3.3.0. Also, the DEGs were applied to the DAVID web-based tool to determine the enrichment of gene functions via Gene Ontology (GO) analysis and to identify associated pathways in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. By constructing protein interaction networks within Cytoscape software, we screened candidate genes and explored possible relationships with the clinical phenotype of PTC. Finally, additional thyroid tissue samples were collected to verify the results above.
Results: After analyzing the RNA-Seq data of PTC patients from the Cancer Genomic Atlas, 497 differentially expressed PTC genes were found to be associated with HT, of which protein tyrosine phosphatase receptor type C (PTPRC), KIT, and COL1A1 were associated with tumor size and lymph node metastasis (p < 0.05). Verification of these results with another 30 thyroid tissues of clinical PTC patients revealed that the expression level of PTPRC in the PTC with HT group was higher than that in the PTC without HT group (p < 0.05) and the ROC curve showed a good discrimination (area under the curve = 0.846). However, the correlation with the clinical phenotype was not statistically significant (p > 0.05).
Discussion: These data suggest that upregulation of PTPRC enhances the incidence of HT associated with PTC and is also predictive of a poor prognosis.
Keywords: papillary thyroid carcinoma, Hashimoto’s thyroiditis, PTPRC, biomarker, prognosis